Fosamax VA Coverage Pathway

Alendronate on the VA National Formulary

Generic alendronate holds a stable position on the VA National Formulary (VANF), the standardized drug list used across all Veterans Health Administration (VHA) facilities. The VA Pharmacy Benefits Management (PBM) program classifies it as a Tier 1 preferred generic bisphosphonate for osteoporosis prevention and treatment [1]. This formulary placement means any VA-enrolled veteran with an active prescription can fill alendronate at a VA pharmacy or through the Consolidated Mail Outpatient Pharmacy (CMOP) system without prior authorization.

The VA's 2023 updated clinical practice guideline for osteoporosis management, developed jointly with the Department of Defense, identifies oral bisphosphonates (alendronate and risedronate) as first-line pharmacotherapy for patients at moderate-to-high fracture risk [2]. A Cochrane systematic review of 12 randomized controlled trials (N=22,120) confirmed that alendronate reduces vertebral fractures by 45% and hip fractures by 40% relative to placebo over 3 to 4 years of treatment [3]. The Fracture Intervention Trial (FIT), which enrolled 6,459 postmenopausal women, showed alendronate 10 mg daily reduced clinical vertebral fracture incidence by 47% at 36 months [4].

Brand-name Fosamax is typically classified as non-formulary because the generic bioequivalent meets FDA therapeutic equivalence standards [5]. Veterans who specifically request brand Fosamax may need a provider to submit a non-formulary request, which the VA medical center's Pharmacy and Therapeutics Committee reviews on a case-by-case basis.

VA Copay Structure for Alendronate

How much a veteran pays depends on their assigned VA priority group. The system uses eight priority groups based on service-connected disability ratings, income, and other factors [6].

Veterans in Priority Groups 1 through 6, which includes those with any service-connected disability rating of 50% or higher, former POWs, Purple Heart recipients, and veterans with qualifying low income, pay $0 for all outpatient medications [7]. This copay exemption applies regardless of whether the medication treats a service-connected condition.

Veterans in Priority Group 7 or 8 pay the standard VA outpatient pharmacy copay. As of 2026, this is $5 for a 30-day supply of a Tier 1 preferred generic like alendronate. The VA caps annual outpatient pharmacy copays at $700 per calendar year for non-exempt veterans [7]. Once a veteran reaches this cap, all subsequent prescriptions for the year cost $0.

The VA CMOP mail-order system ships a 90-day supply directly to a veteran's home. For copay-exempt veterans, this costs nothing. For Priority Group 7 to 8 veterans, the 90-day supply costs approximately $11, making mail order the most economical route [8]. Prescriptions are typically delivered within 3 to 7 business days.

How to Get Alendronate Through the VA

The process starts with enrollment in VA healthcare. Veterans must have served on active duty and received an other-than-dishonorable discharge [6]. Enrollment can be completed online at VA.gov, by phone at 1-877-222-8387, or in person at any VA medical center.

Once enrolled, a veteran schedules an appointment with a VA primary care provider or endocrinologist. The provider evaluates fracture risk using validated tools. The FRAX calculator, developed by the World Health Organization Collaborating Centre, estimates 10-year fracture probability based on clinical risk factors and, optionally, bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA) [9]. The National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation) recommends pharmacotherapy when the 10-year probability of major osteoporotic fracture reaches 20% or hip fracture reaches 3% [10].

If the provider determines alendronate is appropriate, they enter the prescription into the VA's electronic health record (VistA/CPRS or the newer Oracle Health system at transitioning sites). The prescription routes to the VA pharmacy. No prior authorization is needed for formulary generics [1].

Veterans already receiving alendronate from an outside provider can request their VA provider prescribe it through the VA system to reduce costs. The VA will not reimburse prescriptions filled at non-VA commercial pharmacies unless the veteran is approved for community care pharmacy benefits under the MISSION Act [11].

Alendronate Dosing and Administration for VA Patients

The standard dosing for osteoporosis treatment is alendronate 70 mg taken once weekly [5]. For osteoporosis prevention in at-risk patients, the dose is 35 mg once weekly. The VA formulary stocks both strengths.

Proper administration matters for both absorption and esophageal safety. Patients must take alendronate first thing in the morning on an empty stomach with 6 to 8 ounces of plain water only. They should remain upright (sitting or standing) and avoid food, beverages, and other medications for at least 30 minutes after the dose [5]. A post-marketing surveillance study published in the American Journal of Gastroenterology (N=30,606) found that esophageal adverse events occurred in 1.2% of bisphosphonate users, with most cases linked to improper administration [12].

The VA/DoD clinical practice guideline recommends reassessing treatment duration at 3 to 5 years [2]. The FLEX extension trial (N=1,099) demonstrated that women who discontinued alendronate after 5 years maintained reduced vertebral fracture risk over the subsequent 5 years compared to those who never received treatment, though non-vertebral fracture rates were similar between continuation and discontinuation groups [13]. A drug holiday of 2 to 3 years may be appropriate for patients at moderate risk, while those at high risk (T-score of -2.5 or below at the hip, or prior vertebral fracture) may benefit from continued therapy [14].

Comparing VA Coverage to Commercial Insurance

For veterans who also carry private insurance or Medicare Part D, the VA pharmacy benefit is almost always the lower-cost option for generic alendronate.

Under Medicare Part D, generic alendronate falls into Tier 1 on most formularies with copays ranging from $0 to $15 per month depending on the plan [15]. However, veterans in Priority Groups 1 through 6 pay $0 at the VA, and even Priority Group 7 to 8 veterans pay only $5 per month, often less than Part D copays after accounting for the Part D deductible ($590 in 2026).

Commercial insurance plans typically cover generic alendronate with preferred generic copays averaging $3 to $15 per month. Some high-deductible health plans require patients to pay the full retail cost (approximately $15 per month for generic) until meeting the annual deductible. Merck's original Fosamax lost patent exclusivity in 2008, and multiple generic manufacturers now produce alendronate, which keeps cash prices low even without insurance [16].

For veterans without any prescription coverage, GoodRx and similar discount programs list generic alendronate 70 mg (4 tablets for a monthly supply) at $4 to $18 at major retail pharmacies. The VA benefit still beats these prices for copay-exempt veterans and matches them for non-exempt veterans.

When Alendronate Is Not the Right Fit: VA Formulary Alternatives

Some veterans cannot tolerate oral bisphosphonates due to esophageal disorders (Barrett's esophagus, strictures, achalasia), inability to remain upright for 30 minutes, or gastrointestinal side effects. The VA formulary includes several alternatives.

Zoledronic acid (Reclast) is an intravenous bisphosphonate given as a single 5 mg infusion once yearly. The HORIZON Key Fracture Trial (N=7,765) showed zoledronic acid reduced vertebral fractures by 70%, hip fractures by 41%, and non-vertebral fractures by 25% over 3 years [17]. The VA covers this as a facility-administered medication with no separate pharmacy copay.

Denosumab (Prolia) is a RANK ligand inhibitor given as a 60 mg subcutaneous injection every 6 months. It is available on the VA formulary, though some facilities may require non-formulary approval depending on local P&T committee decisions. The FREEDOM trial (N=7,868) demonstrated denosumab reduced vertebral fractures by 68% and hip fractures by 40% over 3 years versus placebo [18]. The FDA issued a boxed warning in 2024 regarding the risk of multiple vertebral fractures after discontinuation, so transition planning is required if therapy is stopped [19].

Raloxifene (Evista) is a selective estrogen receptor modulator (SERM) on the VA formulary, though its fracture reduction is limited to the vertebral spine. The MORE trial (N=7,705) showed raloxifene 60 mg daily reduced vertebral fracture risk by 30% over 3 years, with no significant effect on non-vertebral or hip fractures [20].

Special Considerations for Veterans

Glucocorticoid-induced osteoporosis is common among veterans treated for conditions like COPD, rheumatoid arthritis, and chronic pain. The American College of Rheumatology 2022 guideline recommends oral bisphosphonates as first-line therapy for patients aged 40 and older taking prednisone 2.5 mg or higher daily for 3 months or more who have moderate-to-high fracture risk [21]. VA providers can prescribe alendronate for this indication without additional authorization.

Male veterans represent a significant but underdiagnosed population. Approximately 2 million American men have osteoporosis and another 12 million have osteopenia, yet screening rates remain low [10]. The VA/DoD guideline recommends DXA screening for men aged 70 and older, or aged 50 to 69 with clinical risk factors including glucocorticoid use, low body weight, prior fragility fracture, or androgen deprivation therapy [2]. Alendronate is FDA-approved for osteoporosis in men and carries formulary coverage regardless of sex [5].

Veterans exposed to certain service-related hazards may face elevated fracture risk. A 2019 cohort study of 9,041 male veterans published in the Journal of Bone and Mineral Research found that those with PTSD had a 1.7-fold higher risk of osteoporotic fracture compared to veterans without PTSD, potentially linked to glucocorticoid dysregulation, selective serotonin reuptake inhibitor (SSRI) use, and reduced physical activity [22].

Filing a VA Claim for Osteoporosis as Service-Connected

Veterans who develop osteoporosis related to military service, medications prescribed during service, or service-connected conditions can file a disability compensation claim. If the VA grants service connection for osteoporosis, all related treatment (including alendronate) becomes copay-exempt regardless of priority group.

Common pathways to service connection include secondary connection to a service-connected endocrine condition (hypogonadism, hyperthyroidism), secondary connection to long-term glucocorticoid therapy for a service-connected condition, and direct connection when DXA evidence of bone loss coincides with in-service risk exposures. Claims are filed through VA.gov or with assistance from a Veterans Service Organization (VSO) such as the DAV, VFW, or American Legion [6].

A successful claim at any compensable rating (10% or higher) placed the veteran in Priority Group 1 through 6, eliminating all pharmacy copays. Combined with the formulary status of alendronate, this makes the total out-of-pocket cost for the medication $0 indefinitely.